To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites of FYU-981 after a single 1 mg oral dose of 14C-FYU-981 in healthy male subjects.

Inclusion Criteria:

• Japanese healthy adult subjects
• Body mass index: >=18.5 and <25.0

Exclusion Criteria:

• Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study
• Have participated in a [14C]-study within the last 12 months prior to dosing of the investigational drug
• Exposure to radiation for therapeutic or diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton) within the last 12 months prior to dosing of the investigational drug
• Occupationally exposed worker